Achieve Life Sciences Inc (NASDAQ: ACHV)’s stock price has plunge by 491025relation to previous closing price of 3.35. Nevertheless, the company has seen a 18.15% surge in its stock price over the last five trading sessions. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC bought a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 17,519 shares of the biopharmaceutical company’s stock, valued at approximately $62,000. Squarepoint Ops LLC owned 0.05% of Achieve Life Sciences at the end of the most recent reporting period. A number of other hedge funds and other institutional investors have also bought and sold shares of ACHV. Tower Research Capital LLC TRC raised its holdings in Achieve Life Sciences by 185.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 4,905 shares during the period. Sigma Planning Corp bought a new stake in Achieve Life Sciences during the 4th quarter valued at $37,000. ADAR1 Capital Management LLC raised its holdings in Achieve Life Sciences by 14,375.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 13,082 shares during the period. SBI Securities Co. Ltd. bought a new stake in Achieve Life Sciences during the 4th quarter valued at $49,000. Finally, Intech Investment Management LLC bought a new stake in Achieve Life Sciences during the 4th quarter valued at $58,000. Institutional investors own 33.52% of the company’s stock. Insider Buying and Selling In related news, CFO Mark K. Oki bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $28,900. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is owned by company insiders. Achieve Life Sciences Trading Down 1.9% Shares of ACHV stock opened at $3.69 on Wednesday. The company’s fifty day simple moving average is $2.72 and its two-hundred day simple moving average is $3.16. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences, Inc. has a 1 year low of $1.84 and a 1 year high of $5.38. The stock has a market capitalization of $127.99 million, a price-to-earnings ratio of -3.27 and a beta of 1.63. Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37). As a group, analysts anticipate that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year. Achieve Life Sciences Company Profile (Free Report) Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Is It Worth Investing in Achieve Life Sciences Inc (NASDAQ: ACHV) Right Now?
Company’s 36-month beta value is 1.64.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACHV is 29.37M, and currently, short sellers hold a 8.93% ratio of that floaft. The average trading volume of ACHV on June 24, 2025 was 247.69K shares.
ACHV’s Market Performance
ACHV stock saw an increase of 18.15% in the past week, with a monthly gain of 22.29% and a quarterly increase of 36.65%. The volatility ratio for the week is 7.23%, and the volatility levels for the last 30 days are 6.48% for Achieve Life Sciences Inc (ACHV). The simple moving average for the past 20 days is 10.40% for ACHV’s stock, with a 6.46% simple moving average for the past 200 days.
Analysts’ Opinion of ACHV
Many brokerage firms have already submitted their reports for ACHV stocks, with Rodman & Renshaw repeating the rating for ACHV by listing it as a “Buy.” The predicted price for ACHV in the upcoming period, according to Rodman & Renshaw is $12 based on the research report published on November 14, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see ACHV reach a price target of $20. The rating they have provided for ACHV stocks is “Strong Buy” according to the report published on September 27th, 2024.
Maxim Group gave a rating of “Buy” to ACHV, setting the target price at $20 in the report published on May 10th of the previous year.
ACHV Trading at 32.43% from the 50-Day Moving Average
After a stumble in the market that brought ACHV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACHV starting from Oki Mark K, who purchase 10,000 shares at the price of $2.89 back on Mar 17 ’25. After this action, Oki Mark K now owns 10,000 shares of Achieve Life Sciences Inc, valued at $28,887 using the latest closing price.
Stewart Richard Alistair, the Chieve Executive Officer of Achieve Life Sciences Inc, purchase 10,000 shares at $2.86 during a trade that took place back on Mar 17 ’25, which means that Stewart Richard Alistair is holding 60,876 shares at $28,598 based on the most recent closing price.
Stock Fundamentals for ACHV
The total capital return value is set at -1.02. Equity return is now at value -154.55, with -94.80 for asset returns.
Based on Achieve Life Sciences Inc (ACHV), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -3.57. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is -17.47.
Currently, EBITDA for the company is -37.42 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
Conclusion
In a nutshell, Achieve Life Sciences Inc (ACHV) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
